Stay up-to-date on current diabetes themes, proven therapeutic options, and knowledge resources and tools for you and your patients, and find detailed information on Novo Nordisk diabetes products.
Since the launch of its first pen needle in 1985, Novo Nordisk has been committed to enhancing injection experience by putting technology in patient hands. NovoFine® Plus is the latest example of that commitment.
We have products for rare bleeding disorders, growth hormone-related disorders, and women’s health.
Chronic Weight Management
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
Making a positive difference in people’s lives is at the heart of everything Novo Nordisk does – through groundbreaking science, sustained focus on the environment, and patient-centered care.
Our Media Relations team is ready to help you get all the information you need about Novo Nordisk.
Plainsboro, NJ, Feb. 27, 2018 – Novo Nordisk today announced the submission of a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing Authorization...
Novo Nordisk, a global healthcare company, today announced that Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is now available in the United States for the treatment of hemophilia B.
Novo Nordisk today announced the availability of two new diabetes medications, Ozempic® (semaglutide) injection 0.5 mg or 1 mg and Fiasp® (insulin aspart injection) 100 Units/mL at pharmacies across
Visit the download center to download Novo Nordisk video and more
Sign up to receive our new alerts